TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer

The registry lists NCT07377526 as suspended, last updated 2026-07-31. Enrolment is 37 planned participants, an estimate. Interventions: TGFBR2 KO CAR27/IL-15 NK cells. Primary measures include Safety and Adverse Events (AEs). The registry reason for stopping is: PI Request No results are posted in the registry; this does not exclude separate publications. The title and brief summary specify intraperitoneal cells with oral belzutifan, but the intervention table incorrectly describes the cells as given by mouth; the route is not reproduced as a dosing recommendation.